Skip to main content
SpringerLink
Log in

Biosimilari

Aspetti economici e prospettive per il mercato italiano

Biosimilar drugs: economic issues and Italian market perspectives

  • Published:
PharmacoEconomics Italian Research Articles

Abstract

This article includes (i) a systematic review of the literature on economic issues regarding off-patent bio-drugs market, and (ii) scenarios for biosimilars in Italy. This issue is particularly important, because a growing share of new drugs is derived from biotechnology, patent protections of many of these are expiring and competition on the off-patent market should be promoted to pay for new and innovative drugs.

Literature review is focused on the main differences between drugs derived from chemical synthesis and bio-drugs, as for research and development, production, immunogenicity and its impact on post-marketing studies, regulation (marketing authorisation, pricing, interchangeability) and market structure.

Estimates on the impact of biosimilars on the Italian market rely on the literature review. Hypotheses on biosimilars’ market penetration and price competition from other models have been adapted to the Italian context. These models consider peculiarities of biologics compared to traditional drugs, including a more conservative approach by clinicians due to uncertainty on the risk profile of new biologics launched into the market.

In 2020 savings from biosimilars could range from euro 445 millions (11% of the relevant market) to 575 (14% of the relevant market). The difference between these two scenarios is mostly due to different hypotheses on market penetration and price competition and to the development of biosimilars for monoclonal antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Bibliografia

  1. Pisani J, Bonduelle Y. Opportunities and barriers in the biosimilar market: evolution or revolution for generics companies? London: Pricewaterhouse Coopers LLP 2006 (www.pwc.com/uk/strategy)

    Google Scholar 

  2. Avalere Health. Estimating US savings from follow-on biologics. Biosimilars: how much entry and price competition will result. OHE Conference. London, June 2, 2009

  3. Horikawa H, Tsubouchi M, Kawakami K. Industry views of biosimilar development in Japan. Health Policy 2009; 91: 189–94

    Article  PubMed  Google Scholar 

  4. Lanthier M, Behrman R, Nardinelli C. Economic issues with follow-on protein products. Nat Rev Drug Discov 2008; 7: 733–7

    Article  PubMed  CAS  Google Scholar 

  5. Grabowski H, Wang R. The quantity and the quality of worldwide new drug introductions 1982–2003. Health Aff 2006; 25: 452–60

    Article  Google Scholar 

  6. Jommi C. La valutazione economica dei farmaci biotecnologici. Conferenza Nazionale Farmaci Biotecnologici in Oncologia. Torino, 26–28 novembre 2009

  7. Osservatorio Farmaci. Report 23. Report annuale per il. Milano: Cergas Bocconi, 2008

    Google Scholar 

  8. Genazzani A, Biggio G, Caputi AP, et al. Biosimilar drugs: concerns and opportunities. Biodrugs 2007; 21: 351–6

    Article  PubMed  Google Scholar 

  9. Di Masi J, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics 2007; 28: 469–79

    Article  Google Scholar 

  10. Perayre Badia M, Leiva E, Jódar R. Biotecnológicos y biosimilares: El proceso es el producto. Atención Farmacéutica 2007; 9: 358–64

    Google Scholar 

  11. Tucker J, Yakatan S, Yakatan S. Biogenerics 2007: how far have we come? J Commer Biotechnol 2008; 14: 56–64

    Article  Google Scholar 

  12. Goldsmith D, Kuhlmann M, Covic A. Through the looking glass: the protein science of biosimilars. Clin Exp Nephrol 2007; 11: 191–5

    Article  PubMed  CAS  Google Scholar 

  13. Blackstone AE, Fuhr Jr JP. Why biosimilars will have a smaller competitive edge than generics. Journal of Health Care Finance 2008; 35: 84–95

    Google Scholar 

  14. Tsiftsoglou AS. Biosimilars: the impact of their heterogeneity on regulatory approval. Nat Rev Drug Discov 2007; 6

  15. Schellekens H. Follow-on biologics: challenges of the “next generation”. Nephrol Dial Transplant 2005; 20 Suppl. 4: iv31–6

    Article  PubMed  Google Scholar 

  16. Grabowski HG. The US Data Exclusivity debate: balancing innovation, incentives and cost savings. Biosimilars: how much entry and price competition will result. OHE Conference. London, June 2, 2009

  17. Grabowski HG, Cockburn I, Long G. The market for follow-on biologics: how will it evolve? Health Aff 2006; 25: 1291–301

    Article  Google Scholar 

  18. Grabowski HG. Patents and new product development in the pharmaceutical and biotechnology industries. The Georgetown Public Policy Review 2003; 8: 7–24

    Google Scholar 

  19. Kuhlmann MK, Goldsmith D, Covic A. Biosimilars: current status. Int J Pharm Med 2007; 21: 199–206

    Article  Google Scholar 

  20. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology 2006; 11: 341–6

    Article  PubMed  Google Scholar 

  21. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005; 20 Suppl. 6: vi3–9

    Article  PubMed  CAS  Google Scholar 

  22. Roger SD, Goldsmith D. Biosimilars: it’s not simple as cost alone. J Clin Pharm Ther 2008; 33: 459–64

    Article  PubMed  CAS  Google Scholar 

  23. Sharma B. Immunogenicity of therapeutic proteins. Part 1: impact of product handling. Biotechnol Adv 2007; 25: 310–7

    Article  PubMed  CAS  Google Scholar 

  24. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006; 21 Suppl. 5: v9–12

    Article  PubMed  CAS  Google Scholar 

  25. EMEA. Committee for Medicinal Product for Human Use. Guideline on similar biological medicinal product, 2005 (ultimo accesso: 25 giugno 2009)

  26. Kotlikoff LJ. Biosimilars, data exclusivity and the incentives for innovation: response to Grabowski. Boston University, March 17, 2009

  27. Grabowski HG, Di Masi J. Biosimilars, data exclusivity, and the incentives for innovation: a critique to Kotlikoff’s white paper. Duke University Department of Economics Working paper. No. 2009-02, February 2009

  28. Donnarumma E. Approfondimento su: farmaci biotecnologici e biosimilari. BIF 2008; 15

  29. Duerden M. Prescribing advice needed for new biosimilar biological drugs. Prescriber 2007; 19 novembre 2007, pagine 1–2

    Google Scholar 

  30. (Parere del) Consiglio di Stato, Sezione Prima, 20 giugno 2007: Regione Molise. Quesito sull’applicazione dell’equivalenza terapeutica tra farmaci, nel caso di acquisto di medicinali da parte di pubblici soggetti tramite gar

  31. Tribunale Amministrativo Regionale per l’Emilia Romagna, Sezione Seconda, Sentenza N. 00001/2009 del 2 gennaio 2009

  32. Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologicals. Managerial and Decision Economics 2007; 28: 439–51

    Article  Google Scholar 

  33. Chauhan D, Towse A, Mestre-Ferrandiz J. The markets for biosimilars: evolution and policy options. OHE Briefing 45, October 2008. London: OHE, 2008

    Google Scholar 

  34. Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Marketing Strategy 1997; 6: 75–90

    Article  Google Scholar 

  35. Engel & Novitt. Potential savings that might be realized. A report to PCMA. January 2, 2007 (www.pcmanet.org)

  36. Miller S, Houts J. Potential savings of biogenerics in the United States. Express Scripts 2007 (www.expressscripts.com)

    Google Scholar 

  37. Ahlstrom A, King R, Brown R, et al. Modeling federal cost savings from follow-on biologics. Avalere 2007 (www.avalerehealth.net)

    Google Scholar 

  38. Grabowski HG. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nat Rev Drug Discov 2008; 7: 479–88

    Article  PubMed  CAS  Google Scholar 

  39. Congressional Budget Office, June 25, 2008. Biologics Price Competition and Innovation Act of 2007. Cost estimate for the bill as ordered reported by the Senate Committee on Health, Education, Labor, and Pensions on June 27, 2007 (http://www.cbo.gov/ftpdocs/94xx/doc9496/s1695.pdf)

  40. Patel S. A perspective on the biogeneric opportunity. The S.A.M. Newsletter 2004; 3.3: 4–13

    Google Scholar 

  41. Shapiro RJ. The potential American market for generic biological treatments and the associated cost savings. February 2008

  42. Howrey LLP, Cap Analysis & phRMA. The inflated projections of potential cost savings from follow-on biologics: an analysis of the Express Scripts and Engel & Novitt reports. Howrey Cap Analysis. May 2007

    Google Scholar 

  43. Johnson JA. FDA regulation of follow-on biologics. CRS Report for Congress. Washington, DC: Congressional Research Service, 2009

    Google Scholar 

  44. Gottlieb S. Policy, clinical and regulatory considerations. Am J Health Syst Pharm 2008; 65 Suppl. 6: S2–8

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Scienze Chimiche, Alimentari, Farmaceutiche e Farmacologiche e Facoltà di Farmacia, Università del Piemonte Orientale, Novara, Italia

    C. Jommi

  2. Osservatorio Farmaci, CERGAS, Università Commerciale L. Bocconi, Milano, Italia

    C. Jommi

Authors
  1. C. Jommi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Jommi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jommi, C. Biosimilari. Pharmacoeconomics-Ital-Res-Articles 12, 17–31 (2010). https://doi.org/10.1007/BF03320527

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03320527

Search

Navigation